In September 2016, Joshua Gordon joined the NIH as Director of the National Institute of Mental Health (NIMH). For Gordon, who was previously a psychiatrist and neuroscientist at Columbia University Medical Center, this role presented a once-in-a-lifetime opportunity to oversee a US$1.5 billion budget and shape the future of mental health research. When he started, he said his first order of business would be to listen and learn. One year on, he has heard a lot about the institute's classification of mental illnesses for research purposes (known as RDoC), the appropriate balance between basic and clinical research, and the challenges of using genetics to understand psychiatric disease, he told Asher Mullard.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Rights and permissions
About this article
Cite this article
Joshua Gordon. Nat Rev Drug Discov 16, 523–524 (2017). https://doi.org/10.1038/nrd.2017.134
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.134
